vs

Side-by-side financial comparison of MEDIFAST INC (MED) and TFS Financial CORP (TFSL). Click either name above to swap in a different company.

TFS Financial CORP is the larger business by last-quarter revenue ($83.7M vs $75.1M, roughly 1.1× MEDIFAST INC). On growth, TFS Financial CORP posted the faster year-over-year revenue change (11.9% vs -36.9%). TFS Financial CORP produced more free cash flow last quarter ($57.1M vs $-6.6M). Over the past eight quarters, TFS Financial CORP's revenue compounded faster (4.2% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

TFS Financial Corporation is a US-based financial holding company primarily operating through its retail banking subsidiary. It offers residential mortgage loans, savings accounts, and other consumer financial products, with its core customer base concentrated in Ohio and Florida, mainly serving individual and family clients.

MED vs TFSL — Head-to-Head

Bigger by revenue
TFSL
TFSL
1.1× larger
TFSL
$83.7M
$75.1M
MED
Growing faster (revenue YoY)
TFSL
TFSL
+48.8% gap
TFSL
11.9%
-36.9%
MED
More free cash flow
TFSL
TFSL
$63.7M more FCF
TFSL
$57.1M
$-6.6M
MED
Faster 2-yr revenue CAGR
TFSL
TFSL
Annualised
TFSL
4.2%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MED
MED
TFSL
TFSL
Revenue
$75.1M
$83.7M
Net Profit
$22.3M
Gross Margin
69.4%
Operating Margin
-10.4%
34.0%
Net Margin
26.6%
Revenue YoY
-36.9%
11.9%
Net Profit YoY
-0.7%
EPS (diluted)
$-1.64
$0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
TFSL
TFSL
Q4 25
$75.1M
$83.7M
Q3 25
$89.4M
$85.5M
Q2 25
$105.6M
$82.0M
Q1 25
$115.7M
$79.1M
Q4 24
$119.0M
$74.8M
Q3 24
$140.2M
$75.1M
Q2 24
$168.6M
$75.5M
Q1 24
$174.7M
$77.1M
Net Profit
MED
MED
TFSL
TFSL
Q4 25
$22.3M
Q3 25
$-2.3M
$26.0M
Q2 25
$2.5M
$21.5M
Q1 25
$-772.0K
$21.0M
Q4 24
$22.4M
Q3 24
$1.1M
$18.2M
Q2 24
$-8.2M
$20.0M
Q1 24
$8.3M
$20.7M
Gross Margin
MED
MED
TFSL
TFSL
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
MED
MED
TFSL
TFSL
Q4 25
-10.4%
34.0%
Q3 25
-4.6%
37.9%
Q2 25
-1.0%
33.3%
Q1 25
-1.1%
33.5%
Q4 24
0.6%
37.9%
Q3 24
1.5%
30.7%
Q2 24
-4.7%
33.4%
Q1 24
4.5%
33.6%
Net Margin
MED
MED
TFSL
TFSL
Q4 25
26.6%
Q3 25
-2.5%
30.4%
Q2 25
2.3%
26.2%
Q1 25
-0.7%
26.6%
Q4 24
30.0%
Q3 24
0.8%
24.2%
Q2 24
-4.8%
26.4%
Q1 24
4.8%
26.9%
EPS (diluted)
MED
MED
TFSL
TFSL
Q4 25
$-1.64
$0.08
Q3 25
$-0.21
$0.09
Q2 25
$0.22
$0.08
Q1 25
$-0.07
$0.07
Q4 24
$0.08
$0.08
Q3 24
$0.10
$0.07
Q2 24
$-0.75
$0.07
Q1 24
$0.76
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
TFSL
TFSL
Cash + ST InvestmentsLiquidity on hand
$167.3M
$456.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$1.9B
Total Assets
$248.0M
$17.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
TFSL
TFSL
Q4 25
$167.3M
$456.7M
Q3 25
$173.5M
$429.4M
Q2 25
$162.7M
$452.6M
Q1 25
$164.6M
$463.6M
Q4 24
$162.3M
$465.9M
Q3 24
$170.0M
$463.7M
Q2 24
$163.5M
$560.4M
Q1 24
$156.4M
$594.3M
Stockholders' Equity
MED
MED
TFSL
TFSL
Q4 25
$198.9M
$1.9B
Q3 25
$214.7M
$1.9B
Q2 25
$216.0M
$1.9B
Q1 25
$211.0M
$1.9B
Q4 24
$210.1M
$1.9B
Q3 24
$207.3M
$1.9B
Q2 24
$205.3M
$1.9B
Q1 24
$211.0M
$1.9B
Total Assets
MED
MED
TFSL
TFSL
Q4 25
$248.0M
$17.5B
Q3 25
$268.2M
$17.5B
Q2 25
$269.3M
$17.4B
Q1 25
$280.0M
$17.1B
Q4 24
$284.2M
$17.1B
Q3 24
$291.2M
$17.1B
Q2 24
$293.5M
$17.0B
Q1 24
$302.8M
$17.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
TFSL
TFSL
Operating Cash FlowLast quarter
$-5.3M
$58.7M
Free Cash FlowOCF − Capex
$-6.6M
$57.1M
FCF MarginFCF / Revenue
-8.8%
68.2%
Capex IntensityCapex / Revenue
1.8%
2.0%
Cash ConversionOCF / Net Profit
2.64×
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$167.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
TFSL
TFSL
Q4 25
$-5.3M
$58.7M
Q3 25
$12.1M
$82.4M
Q2 25
$-3.4M
$26.8M
Q1 25
$3.4M
$21.2M
Q4 24
$-4.9M
$45.5M
Q3 24
$9.1M
$88.6M
Q2 24
$13.1M
$96.7M
Q1 24
$7.3M
$14.2M
Free Cash Flow
MED
MED
TFSL
TFSL
Q4 25
$-6.6M
$57.1M
Q3 25
$10.8M
$71.0M
Q2 25
$-4.8M
$25.0M
Q1 25
$1.9M
$14.3M
Q4 24
$-7.2M
$44.9M
Q3 24
$7.7M
$85.5M
Q2 24
$11.1M
$95.9M
Q1 24
$5.4M
$13.4M
FCF Margin
MED
MED
TFSL
TFSL
Q4 25
-8.8%
68.2%
Q3 25
12.0%
83.0%
Q2 25
-4.5%
30.5%
Q1 25
1.6%
18.0%
Q4 24
-6.1%
60.0%
Q3 24
5.5%
113.8%
Q2 24
6.6%
127.0%
Q1 24
3.1%
17.4%
Capex Intensity
MED
MED
TFSL
TFSL
Q4 25
1.8%
2.0%
Q3 25
1.5%
13.4%
Q2 25
1.3%
2.1%
Q1 25
1.3%
8.8%
Q4 24
1.9%
0.9%
Q3 24
1.0%
4.1%
Q2 24
1.1%
1.1%
Q1 24
1.1%
1.1%
Cash Conversion
MED
MED
TFSL
TFSL
Q4 25
2.64×
Q3 25
3.17×
Q2 25
-1.36×
1.24×
Q1 25
1.01×
Q4 24
2.03×
Q3 24
8.04×
4.86×
Q2 24
4.85×
Q1 24
0.88×
0.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons